Shlomo Yellinek

Shlomo Yellinek

Auto-generated profile, based on publicly available information

Shlomo Yellinek

Department of General Surgery, Shaare Zedek Medical Center The Hebrew University School of Medicine Jerusalem Israel

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2019 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
James TankelJames Tankel
James Tankel
SYShlomo Yellinek
Shlomo Yellinek
EVElena Vainberg
Elena Vainberg
YDYotam David
Yotam David
DGDmitry Greenman
Dmitry Greenman
PRPetachia Reissman
Petachia Reissman

27 May 2020 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
HGHayim Gilshtein
Hayim Gilshtein
SYS. Yellinek
S. Yellinek
JMJ. Maenza
J. Maenza
SWSteven D. Wexner
Steven D. Wexner

7 December 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
EBElad Boaz
Elad Boaz
EBEli Ben-Chetrit
Eli Ben-Chetrit
YBYonathan Bokhobza
Yonathan Bokhobza
SYShlomo Yellinek
Shlomo Yellinek
MBMenahem Ben-Haim
Menahem Ben-Haim
ADAmir Dagan
Amir Dagan
Background. Pyogenic liver abscess (PLA) is an uncommon but potentially life‐threatening condition. In recent years, advances in diagnostics and management have led to early diagnosis and treatment and decreased mortality. We present recent data from a large series of patients with PLA and examine the trends in the management of PLA over a period of 50 years. Methods. The medical records of all patients admitted to the Shaare Zedek Medical Center, Israel, between January 2011 and December 2021 with a primary or secondary diagnosis of PLA were reviewed retrospectively. Results: Ninety‐five patients with PLA were identified. Thirty‐eight (40%) were female. The median patient age was 66 years (range 18–93). The diagnosis of PLA in all patients was confirmed with abdominal computed tomography (CT). In twenty patients (21.1%), PLA was not diagnosed by the initial abdominal US. Most abscesses were right‐sided. Biliary tract origin was the most common underlying cause of PLA (n = 57, 60%), followed by cryptogenic etiology (n = 28, 30%). Escherichia coli, Klebsiella pneumoniae, and Streptococcus species were most commonly identified. The most common primary treatment modality was percutaneous drainage (PD), which was performed in 81 patients (85.3%). Fourteen patients (14.7%) were treated medically without intervention, and two patients (2.1%) were treated surgically following a failure of PD. Four patients died as a direct result of PLA. Conclusions. Patients diagnosed with PLA are older, the male predominance is less pronounced, and the offending pathogens are likely to originate from the biliary tract. This study questions the utility of abdominal US as the initial diagnostic imaging in patients with suspected PLA (versus CT) and demonstrates improved outcomes for patients with PLA over the years.

28 October 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PBPéter Bacsur 
Péter Bacsur 
DSDaniel Shaham
Daniel Shaham
ZSZuzana Serclova
Zuzana Serclova
TRTamás Resál
Tamás Resál
BFBernadett Farkas
Bernadett Farkas
TMTamás Molnár
Tamás Molnár
Background: Perianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety of adipose‐derived mesenchymal stem cell treatment are contradicting, and real‐world evidence is lacking.Aims: To examine the usability of darvadstrocel therapy in managing perianal CD.Methods: We enrolled patients with CD and perianal fistulas in this retrospective multicenter study. The primary outcome was perianal clinical remission (defined as all treated fistulas closed) at weeks 26 and 52. Secondary outcomes were clinical response rates (≥ 1 fistulas closed), perianal activity (PDAI), patient satisfaction, and adverse events. Data were recorded at baseline and weeks 12, 26 and 52. Prediction of primary outcomes was performed by logistic regression.Results: Overall, among 223 patients (male/female ratio: 0.48), perianal clinical remission was achieved in 78.2% and 62.3% until weeks 26 and 52. Baseline PDAI score (OR 0.75), number of fistulas (OR 0.28) and the number of weeks after preparation for surgery (OR 0.98) were associated with treatment failure. The clinical response rates were 84.8% and 79.8% at weeks 26 and 52. Improvement of subjective perianal symptoms was achieved in 77.8% and 78.4% of patients, respectively. Adverse events occurred in 13.5% of patients; perianal abscesses and proctalgia were the most frequently reported.Conclusion: Effectiveness data were higher than in clinical trials. The safety profile was reassuring, and patients' satisfaction was high. Appropriate patient selection, fistula preparation and expertise may help to achieve treatment success.

5 August 2022 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
EBElad Boaz
Elad Boaz
ASAriella Bar-Gil Shitrit
Ariella Bar-Gil Shitrit
MSMenachem Schechter
Menachem Schechter
EGEran Goldin
Eran Goldin
PRPetachia Reissman
Petachia Reissman
BKBenjamin Koslowsky
Benjamin Koslowsky
Family history increases the risk for inflammatory bowel diseases (IBDs). However, data on differences in phenotypic characteristics among patients with a strong family history of IBD are scarce and controversial. The aim of the study was to compare the phenotypic features of IBD patients with four or more affected first-degree relatives with sporadic cases of IBD. Patients with familial and sporadic IBD were identified from the institutional IBD database. IBD patients from families with at least four first-degree affected relatives were selected for analysis and were compared to non-matched sporadic cases with IBD chosen randomly. Comparison for type of IBD (Crohn’s disease (CD) vs. ulcerative colitis (UC)), age at onset as well as for disease extent, behavior, extraintestinal manifestations and indicators of severe disease were analyzed. Thirty-five patients with familial IBD (28 CD, seven UC) were compared to 88 sporadic IBD patients (61 CD, 24 UC and three IBDU). Disease duration was 10.3 ± 8.2 in the familial and 8.0 ± 7.2 years in the sporadic cases, p=.13. The familial cases were younger at diagnosis (19.3 ± 8.6 vs. 25.7 ± 11.8, p=.004). Patients with familial compared to sporadic IBD were significantly more likely to require steroid treatment (80% vs. 54.5%, p=.009), biological treatment (94.3%, vs. 63.6%, p<.001) or surgery (25.7%, vs. 11.4%, p=.048). IBD with a very strong positive family history is associated with younger age at onset and a more adverse IBD phenotype compared to sporadic IBD.